MINOX SOLUTION

Land: Canada

Språk: engelsk

Kilde: Health Canada

Aktiv ingrediens:

MINOXIDIL

Tilgjengelig fra:

LABORATOIRE RIVA INC.

ATC-kode:

D11AX01

INN (International Name):

MINOXIDIL, TOPICAL

Dosering :

20MG

Legemiddelform:

SOLUTION

Sammensetning:

MINOXIDIL 20MG

Administreringsrute:

TOPICAL

Enheter i pakken:

250ML

Resept typen:

OTC

Terapeutisk område:

MISC. SKIN AND MUCOUS MEMBRANE AGENTS

Produkt oppsummering:

Active ingredient group (AIG) number: 0114429001; AHFS:

Autorisasjon status:

APPROVED

Autorisasjon dato:

2022-09-29

Preparatomtale

_MINOX (Minoxidil Topical Solution) _
_Page 1 of 33_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
MINOX
Minoxidil Topical Solution
20 mg/mL (2% w/v)
USP
Hair Regrowth Treatment
THIS PRODUCT IS FOR MEN ONLY
LABORATOIRE RIVA INC.
660 Boul. Industriel
Blainville, Quebec
J7C 3V4
www.labriva.com
Date of Initial Authorization:
August 19, 1996
Date of Revision:
August 4, 2022
Submission Control Number: 263345
_MINOX (Minoxidil Topical Solution) _
_Page 2 of 33_
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics...........................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
4
DOSAGE AND
ADMINISTRATION.................................................................................
5
4.1
Dosing Considerations
.......................................................................................
5
4.2
Recommended Dose and Dosage
Adjustment..................................................... 5
4.4
Administration...................................................................................................
5
4.5
Missed Dose
......................................................................................................
6
5
OVERDOSAGE
.............................................................................................................
6
6
DOSAGE FORMS, STRENGTHS, COMPOSI